# HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

> **NCT03786107** · — · TERMINATED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 1583 (actual)

## Conditions studied

- Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- Metastatic Cervical Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Almac HER-Seq Assay

## Key facts

- **NCT ID:** NCT03786107
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-14
- **Primary completion:** 2021-01-21
- **Final completion:** 2021-01-21
- **Target enrollment:** 1583 (ACTUAL)
- **Why stopped:** The study was stopped early due to increased global access to genomic screening. It is no longer economical to continue with this particular single-gene screening protocol.
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786107, "HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03786107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*